212 related articles for article (PubMed ID: 32337896)
21. Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center.
Takai C; Ito S; Kobayashi D; Nemoto T; Lee H; Abe A; Otani H; Nakazono K; Murasawa A; Ishikawa H
Intern Med; 2020; 59(16):1963-1970. PubMed ID: 32801270
[TBL] [Abstract][Full Text] [Related]
22. The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.
Salaffi F; Ciapetti A; Gasparini S; Carotti M; Bombardieri S;
Clin Exp Rheumatol; 2012; 30(6):912-21. PubMed ID: 22935335
[TBL] [Abstract][Full Text] [Related]
23. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
Pincus T; Furer V; Keystone E; Yazici Y; Bergman MJ; Luijtens K
Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1142-9. PubMed ID: 21485024
[TBL] [Abstract][Full Text] [Related]
24. FCGR2A/FCGR3A Gene Polymorphisms and Clinical Variables as Predictors of Response to Tocilizumab and Rituximab in Patients With Rheumatoid Arthritis.
Jiménez Morales A; Maldonado-Montoro M; Martínez de la Plata JE; Pérez Ramírez C; Daddaoua A; Alarcón Payer C; Expósito Ruiz M; García Collado C
J Clin Pharmacol; 2019 Apr; 59(4):517-531. PubMed ID: 30457672
[TBL] [Abstract][Full Text] [Related]
25. Contribution of subjective Disease Activity Score 28 (DAS28) components to the response to treatment of rheumatoid arthritis.
Son KM; Lee SY; Seo YI; Choi JE; Kim HA
Clin Rheumatol; 2017 Jun; 36(6):1221-1227. PubMed ID: 28451869
[TBL] [Abstract][Full Text] [Related]
26. Serum level of reactive oxygen metabolites (ROM) at 12 weeks of treatment with biologic agents for rheumatoid arthritis is a novel predictor for 52-week remission.
Nakajima A; Aoki Y; Sonobe M; Takahashi H; Saito M; Nakagawa K
Clin Rheumatol; 2017 Feb; 36(2):309-315. PubMed ID: 27858176
[TBL] [Abstract][Full Text] [Related]
27. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
Kim SK; Choe JY; Park SH; Lee H
Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
[TBL] [Abstract][Full Text] [Related]
28. Remission in rheumatoid arthritis by different criteria does not converge over the inflammatory markers.
Chandrashekara S; Priyanka BU
Int J Rheum Dis; 2013 Jun; 16(3):291-6. PubMed ID: 23981750
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis.
Roshique KK; Ravindran V
Clin Rheumatol; 2015 Jul; 34(7):1289-92. PubMed ID: 26032432
[TBL] [Abstract][Full Text] [Related]
30. The impact of different criteria sets on early remission and identifying its predictors in rheumatoid arthritis: results from an observational cohort (2009-2018).
Xie W; Li J; Zhang Z
Clin Rheumatol; 2020 Feb; 39(2):381-389. PubMed ID: 31709477
[TBL] [Abstract][Full Text] [Related]
31. Relationship between neutrophil-lymphocyte, platelet-lymphocyte ratio and disease activity in rheumatoid arthritis treated with rituximab.
Sargin G; Senturk T; Yavasoglu I; Kose R
Int J Rheum Dis; 2018 Dec; 21(12):2122-2127. PubMed ID: 30338636
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of golimumab in Indian patients with rheumatoid arthritis: Subgroup data from GO-MORE study.
Pal S; Veeravalli SC; Das SK; Shobha V; Uppuluri RR; Dharmanand BG; Nadkar M; Hsia E; Fei K; Yao R; Khalifa A
Int J Rheum Dis; 2016 Nov; 19(11):1083-1092. PubMed ID: 27457311
[TBL] [Abstract][Full Text] [Related]
33. Individual therapeutic DAS28-d
Koehm M; McIntosh MJ; Hofmann MW; Abraham V; Gabay C; Choy EH; Kavanaugh A; Burkhardt H; Behrens F
Rheumatol Int; 2020 May; 40(5):747-755. PubMed ID: 32040761
[TBL] [Abstract][Full Text] [Related]
34. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.
Tanaka Y; Hirata S; Kubo S; Fukuyo S; Hanami K; Sawamukai N; Nakano K; Nakayamada S; Yamaoka K; Sawamura F; Saito K
Ann Rheum Dis; 2015 Feb; 74(2):389-95. PubMed ID: 24288014
[TBL] [Abstract][Full Text] [Related]
35. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
[TBL] [Abstract][Full Text] [Related]
37. Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab.
Hirata S; Marotta A; Gui Y; Hanami K; Tanaka Y
Arthritis Res Ther; 2015 Oct; 17():280. PubMed ID: 26449724
[TBL] [Abstract][Full Text] [Related]
38. Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial.
Ormseth MJ; Oeser AM; Cunningham A; Bian A; Shintani A; Solus J; Tanner S; Stein CM
Arthritis Res Ther; 2013; 15(5):R110. PubMed ID: 24020899
[TBL] [Abstract][Full Text] [Related]
39. Biomarkers in Remission According to Different Criteria in Patients with Rheumatoid Arthritis.
Yilmaz-Oner S; Ozen G; Can M; Atagunduz P; Direskeneli H; Inanc N
J Rheumatol; 2015 Nov; 42(11):2066-70. PubMed ID: 26472417
[TBL] [Abstract][Full Text] [Related]
40. Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice.
Notario Ferreira I; Ferrer González MA; Morales Garrido P; González Utrilla A; García Sanchez A; Soto Pino MJ; Suero Rosario E; Caro Hernández C; Añón Oñate I; Pérez Albaladejo L; Cáliz Cáliz R
Reumatol Clin; 2017; 13(2):78-84. PubMed ID: 27174398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
